Trial · NCT04578847
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
NCT04578847, Phase 2, Unknown, National Research Center for Hematology, Russia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib). Trials, record NCT04578847. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04578847
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
- NCT number
- NCT04578847
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- National Research Center for Hematology, Russia
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia
- Interventions
- Imatinib, Nilotinib, Dasatinib, Bosutinib
- First posted
- 2020-10-08
- Last updated
- 2020-10-08
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival, survival without molecular relapse | 37 months | |
| Secondary | The proportion of patients with molecular relapse who achieved MMR and DMR after the resumption TKI therapy in standard doses | 37 months | |
| Secondary | The proportion of patients who resolved the adverse events after TKI dose reduction and discontinuation of TKI therapy | 37 months | |
| Secondary | The proportion of patients who have TKI withdrawal syndrome after TKI dose reduction and discontinuation of TKI therapy. | 37 months | |
| Secondary | Clinical factors, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | sex (male, female) |
| Secondary | Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | age |
| Secondary | Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | risk group (Sokal, ELTS) at the time of diagnosis |
| Secondary | Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | duration of previous TKI treatment |
| Secondary | Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | Duration of molecular response |
| Secondary | Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI. | 37 months | Molecular response at the time of inclusion in the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04578847
GET https://conductscience.org/api/trials/v1/NCT04578847/registered